Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ventavis · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Ventavis (Iloprost, BAYQ6256) | DRUG | Inhaled iloprost |
Inclusion Criteria: * Completion of the 12-week treatment period of the predecessor Schering study 97218/300180 * Investigator judged iloprost aerosol therapy warranted as a suitable treatment for the respective patient * Negative pregnancy test for females Exclusion Criteria: * Any condition dur...
Ventavis is used for pulmonary hypertension, a condition of high blood pressure in the arteries of the lungs. It is an inhaled small molecule developed by Bayer AG under the ticker BAYRY. The clinical program studied patients with primary or secondary pulmonary hypertension, and the drug is given by inhalation.
Ventavis is developed by Bayer AG, which trades over the counter in the United States under the ticker BAYRY. Bayer sponsored the clinical trial program for the drug in pulmonary hypertension, including the AIR-II study and a long-term safety follow-up study conducted across several European countries.
Ventavis has been studied in Phase 3 clinical development for pulmonary hypertension. Two completed trials are registered, one Phase 2 study and one Phase 3 safety follow-up study, with a combined enrollment of 134 patients. No trials are currently listed as active.
Two completed trials of Ventavis are registered. NCT00414687, the Aerosolized Randomized Iloprost Study II (AIR-II), was a Phase 2 trial in 63 patients with primary or secondary pulmonary hypertension. NCT00185315 was a Phase 3 safety follow-up study of inhaled iloprost in 71 patients, run in Belgium, France, Italy, Netherlands, Poland, Portugal and Spain.
Yes. Ventavis is the brand name for iloprost, and the compound is also identified by the code BAYQ6256. Searches for Ventavis, iloprost, or BAYQ6256 refer to the same inhaled small molecule developed by Bayer AG for pulmonary hypertension.
The registered Ventavis studies enrolled adults 18 years and older of both sexes, and both were randomized. The Phase 2 AIR-II trial enrolled 63 patients and the Phase 3 safety follow-up study enrolled 71 patients. Neither study used a controlled design, and patients were not selected by biomarker.